From the perspective of the relationship between astrocyte glycolysis and the course of AD, glucagon-like peptide-1 has been shown to provide neuroprotection in patients, with the underlying mechanism involving activation of the PI3K/Akt pathway, which also provides us with a means to intervene in the progression of AD through astrocytes (Zheng et al., 2021). This evidence concerns the gene AKT1 and Alzheimer disease.